22DRA432:Randomized,Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-na�ve Subjects with Advanced or Metastatic PD-L1 High (TPS =50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (Tropion-Lu
Principal Investigator
Study Number
STUDY02001432
Summary
This is a study for adult patients with non-small cell lung cancer (NSCLC) that is advanced or has spread. Your cancer also has a protein called PD-L1. PD-L1 allows some cells to escape an attack by the immune system. The PD-L1 level determines whether you could benefit from cancer drugs known as immune checkpoint inhibitors (drugs that enable your body's immune system to act against your cancer). The main purpose of this research study is to gather information about an investigational drug (a drug that is being studied and has not been approved by the FDA), datopotamab deruxtecan (Dato-DXd) in combination with approved drug pembrolizumab versus pembrolizumab alone, in treating your disease. Patients will be assigned to one of 2 study arms by chance (similar to taking numbers out of a hat) and you will have equal chances of receiving treatment in Arm 1 or Arm 2 of the study.
Phase
III
Contact
Available at the following location(s)
- Lebanon
View more details at ClinicalTrials.gov
Do you need help with some of the labels on this page?
Read our glossary of terms